PureTech Health PLC News - PRTC

PureTech to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression

A placebo-controlled, Phase 2a, proof-of-concept, social anxiety clinical trial in healthy volunteers is...

Schedule 13g
(sc 13g/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...

PureTech to Present at the SVB Securities Global Biopharma Conference

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...

PureTech Provides End of Year Report on Key Progress

Rapid advancement of PureTech’s Wholly Owned Pipeline, with three clinical trials now underway and five completed this year that demonstrated...

PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers

Orally administered LYT-300 achieved blood levels of allopregnanolone at or above those associated with...

PureTech to Present at 41st Annual J.P. Morgan Healthcare Conference

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics...

PureTech Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology (ASH) Annual Meeting

Data support the role of galectin-9 in multiple types of leukemia and the ability of anti-galectin-9...

PureTech Founded Entity Sonde Health Raises $19.25 Million Series B for Voice-Based Health Monitoring

AI vocal biomarker company will use funding to accelerate its commercial growth, expand its platform into new health conditions, and enter new...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...

PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform

LYT-310 demonstrated three to fourfold increase in oral bioavailability of CBD compared to unmodified CBD in a...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

PureTech Health PLC (PRTC)

Empower your portfolio: Real-time discussions and actionable trading ideas.

PRTC News

PureTech to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression

Schedule 13g
(sc 13g/a)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

PureTech to Present at the SVB Securities Global Biopharma Conference

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

PureTech Provides End of Year Report on Key Progress

PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers

PureTech to Present at 41st Annual J.P. Morgan Healthcare Conference

PureTech Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology (ASH) Annual Meeting

PureTech Founded Entity Sonde Health Raises $19.25 Million Series B for Voice-Based Health Monitoring

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform

PureTech to Present at Two Upcoming Investor Conferences

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

PureTech to Present at the Jefferies London Healthcare Conference

PRTC Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

PureTech Health PLC (PRTC) News

PureTech Health PLC (PRTC)

Empower your portfolio: Real-time discussions and actionable trading ideas.

PRTC News

PureTech to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression

Schedule 13g (sc 13g/a)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

PureTech to Present at the SVB Securities Global Biopharma Conference

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

PureTech Provides End of Year Report on Key Progress

PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers

PureTech to Present at 41st Annual J.P. Morgan Healthcare Conference

PureTech Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology (ASH) Annual Meeting

PureTech Founded Entity Sonde Health Raises $19.25 Million Series B for Voice-Based Health Monitoring

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform

PureTech to Present at Two Upcoming Investor Conferences

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

PureTech to Present at the Jefferies London Healthcare Conference

PRTC Discussion

Your Recent History

Schedule 13g
(sc 13g/a)